Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients. [electronic resource]
Producer: 20180706Description: 1368-1372 p. digitalISSN:- 1473-5687
- Adult
- Alanine Transaminase -- blood
- Antiviral Agents -- therapeutic use
- Aspartate Aminotransferases -- blood
- Bilirubin -- blood
- Carbamates
- Drug Therapy, Combination
- Egypt
- End Stage Liver Disease -- physiopathology
- Female
- Hepatitis C, Chronic -- blood
- Humans
- Imidazoles -- therapeutic use
- International Normalized Ratio
- Male
- Middle Aged
- Platelet Count
- Prospective Studies
- Pyrrolidines
- Ribavirin -- therapeutic use
- Serum Albumin -- metabolism
- Severity of Illness Index
- Sofosbuvir -- therapeutic use
- Sustained Virologic Response
- Valine -- analogs & derivatives
No physical items for this record
Publication Type: Journal Article; Observational Study
There are no comments on this title.
Log in to your account to post a comment.